GlassScriptPhysician profile
Mary Pruitt
NPI 1275841199
$6,728.60
in general payments reported to CMS, 2019-2025
32 companies · $1,592 in 2025
The $1,592 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,089 · 2022: $1,534 · 2023: $1,109 · 2024: $1,404 · 2025: $1,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,105.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,949.24 | 2021-2025 | |
| Novo Nordisk INC | $1,178.02 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $883.81 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $728.51 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $233.69 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $227.08 | 2024-2025 | Caplyta |
| Lilly USA, LLC | $221.87 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $181.91 | 2024-2025 | |
| Amgen INC. | $150.88 | 2021-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $142.14 | 2025 | Veozah |
| Organon LLC | $127.94 | 2021-2025 | Nexplanon |
| Abbott Laboratories | $125.79 | 2021-2025 | Freestyle Libre 3 |
| Lundbeck LLC | $71.21 | 2024-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $57.59 | 2021-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Dexcom, INC. | $57.29 | 2025 | Dexcom G6 Transmitter |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $56.66 | 2025 | General - Pain Management |
| Mylan Specialty L.P. | $31.35 | 2021-2022 | |
| Glaxosmithkline, LLC. | $31.34 | 2024-2025 | Bexsero, Shingrix, Arexvy |
| Alkermes, INC. | $27.56 | 2024 | Vivitrol |
| Sunovion Pharmaceuticals INC. | $26.56 | 2021 | |
| Gilead Sciences, INC. | $24.45 | 2025 | Yeztugo |
| Vanda Pharmaceuticals INC. | $22.96 | 2021 | |
| Indivior INC. | $22.34 | 2025 | Sublocade |
| Medline Industries LP | $18.84 | 2024 | Medline Industries, INC. |
| Esperion Therapeutics, INC. | $18.49 | 2025 | Nexletol |
| Actelion Pharmaceuticals US, INC. | $18.41 | 2025 | Uptravi, Opsumit |
| Takeda Pharmaceuticals U.S.A., INC. | $17.85 | 2021 | |
| Uswm, LLC | $15.41 | 2021 | |
| Scynexis, INC. | $15.22 | 2022 | |
| Metacel Pharmaceuticals LLC | $15.03 | 2023 | Ozobax |
| Xeris Pharmaceuticals, INC. | $14.59 | 2025 | Gvoke Hypopen |
| Axsome Therapeutics, INC. | $14.57 | 2024 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Pruitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.